Literature DB >> 16263229

Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.

Ahmed S Guinedi1, Nahed D Mortada, Samar Mansour, Rania M Hathout.   

Abstract

Niosomes have been reported as a possible approach to improve the low corneal penetration and bioavailability characteristics shown by conventional ophthalmic vehicles. Niosomes formed from Span 40 or Span 60 and cholesterol in the molar ratios of 7:4, 7:6 and 7:7 were prepared using reverse-phase evaporation and thin film hydration methods. The prepared systems were characterized for entrapment efficiency, size, shape and in vitro drug release. Stability studies were carried out to investigate the leaching of drug from niosomes during storage. The intraocular pressure (IOP) lowering activity of acetazolamide niosomal formulations in rabbits was measured using ShiØtz tonometer. Histological examination for the corneal tissues of rabbits receiving niosomal formulations was carried out for assessment of the ocular irritancy of niosomes. The results showed that the type of surfactant, cholesterol content and the method of preparation altered the entrapment efficiency and drug release rate from niosomes. Higher entrapment efficiency was obtained with multilamellar niosomes prepared from Span 60 and cholesterol in a 7:6 molar ratio. Niosomal formulations have shown a fairly high retention of acetazolamide inside the vesicles (approximately 75%) at a refrigerated temperature up to a period of 3 months. Each of the tested acetazolamide niosomes prepared by either method produced a significant decrease in IOP compared to the solution of free drug and plain niosomes. Multilamellar acetazolamide niosomes formulated with Span 60 and cholesterol in a 7:4 molar ratio were found to be the most effective and showed prolonged decrease in IOP. Histological examination of corneal tissues after instillation of niosomal formulation for 40 days showed slight irritation in the substantia propria of the eye which is reversible and no major changes in tissues were observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263229     DOI: 10.1016/j.ijpharm.2005.09.023

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  52 in total

1.  Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: in vitro and in vivo evaluation.

Authors:  Sabyasachi Maiti; Sayon Paul; Ranjit Mondol; Somasree Ray; Biswanath Sa
Journal:  AAPS PharmSciTech       Date:  2011-06-14       Impact factor: 3.246

2.  Proniosomal oral tablets for controlled delivery and enhanced pharmacokinetic properties of acemetacin.

Authors:  Tamer M Shehata; Marwa H Abdallah; Mahmoud Mokhtar Ibrahim
Journal:  AAPS PharmSciTech       Date:  2014-10-16       Impact factor: 3.246

3.  Preparation and characterization of niosomal gel for iontophoresis mediated transdermal delivery of isosorbide dinitrate.

Authors:  Sanyog Jain; Bankim H Chaudhari; Nitin K Swarnakar
Journal:  Drug Deliv Transl Res       Date:  2011-08       Impact factor: 4.617

4.  pH-sensitive pHLIP® coated niosomes.

Authors:  Mohan C Pereira; Monica Pianella; Da Wei; Anna Moshnikova; Carlotta Marianecci; Maria Carafa; Oleg A Andreev; Yana K Reshetnyak
Journal:  Mol Membr Biol       Date:  2017-08-09       Impact factor: 2.857

5.  Encapsulation of Leflunomide (LFD) in a novel niosomal formulation facilitated its delivery to THP-1 monocytic cells and enhanced Aryl hydrocarbon receptor (AhR) nuclear translocation and activation.

Authors:  Mahsa Hasani; Neda Abbaspour Sani; Behnaz Khodabakhshi; Mehdi Sheikh Arabi; Saeed Mohammadi; Yaghoub Yazdani
Journal:  Daru       Date:  2019-08-20       Impact factor: 3.117

6.  Treatment of Brucellosis in Guinea Pigs via a Combination of Engineered Novel pH-Responsive Curcumin Niosome Hydrogel and Doxycycline-Loaded Chitosan-Sodium Alginate Nanoparticles: an In Vitro and In Vivo Study.

Authors:  Fatma I Abo El-Ela; Khaled H Hussein; Hossny A El-Banna; Amr Gamal; Sherin Rouby; Ahmed M S Menshawy; El-Shimaa El-Nahass; Shehata Anwar; Mohamed M A Zeinhom; Heba F Salem; Marawa Ahmed Yahia Al-Sayed; Hala A El-Newery; Khaled A M Shokier; Khalid A El-Nesr; H I Hosein
Journal:  AAPS PharmSciTech       Date:  2020-11-18       Impact factor: 3.246

7.  PEGylated synthetic surfactant vesicles (Niosomes): novel carriers for oligonucleotides.

Authors:  Yongzhuo Huang; Jinliang Chen; Xiaojin Chen; Jianqing Gao; Wenquan Liang
Journal:  J Mater Sci Mater Med       Date:  2007-07-10       Impact factor: 3.896

8.  Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes.

Authors:  Varaporn Buraphacheep Junyaprasert; Veerawat Teeranachaideekul; Tasaneeya Supaperm
Journal:  AAPS PharmSciTech       Date:  2008-07-18       Impact factor: 3.246

9.  Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.

Authors:  Zerrin Sezgin-Bayindir; Mustafa Naim Antep; Nilufer Yuksel
Journal:  AAPS PharmSciTech       Date:  2014-09-10       Impact factor: 3.246

10.  A novel nanogel loaded with chitosan decorated bilosomes for transdermal delivery of terbutaline sulfate: artificial neural network optimization, in vitro characterization and in vivo evaluation.

Authors:  Shahira F El Menshawe; Heba M Aboud; Mohammed H Elkomy; Rasha M Kharshoum; Amany M Abdeltwab
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.